LakeShore Biopharma Co. L... (LSB)
NASDAQ: LSB
· Real-Time Price · USD
0.76
-0.03 (-3.80%)
At close: Aug 15, 2025, 12:51 PM
Company Description
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer.
The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.
It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines.
The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024.
LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.
LakeShore Biopharma Co. Ltd

Country | CN |
IPO Date | Aug 5, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 758 |
CEO | Wang Xu |
Contact Details
Address: Building No. 2 Beijing, CN | |
Website | https://www.ysbiopharm.com |
Stock Details
Ticker Symbol | LSB |
Exchange | NASDAQ |
Fiscal Year | April - March |
Reporting Currency | USD |
CIK Code | 0001946399 |
CUSIP Number | n/a |
ISIN Number | KYG9845F1090 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Wang Xu | Chief Executive Officer & Director |
Rui Yu M.B.A., M.S. | Chief Financial Officer & Director |
Dr. Hui Shao C.F.A., M.B.A., Ph.D. | President, Chief Business Officer & Vice Chairman |
Dr. Yuan Liu Ph.D. | Head of Vaccine Research |
Dr. Zenaida Reynoso Mojares M.D. | Chief Medical Officer |
Zhiyuan Ran | Head of Medical & Marketing Department |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jul 31, 2025 | 6-K | Filing |
Jul 31, 2025 | 20-F | Filing |
Jul 22, 2025 | SCHEDULE 13D | Filing |
Jul 15, 2025 | SCHEDULE 13D/A | [Amend] Filing |
Jul 15, 2025 | 6-K | Filing |
Jul 08, 2025 | 6-K | Filing |
May 12, 2025 | 6-K | Filing |
May 06, 2025 | 6-K | Filing |
Mar 25, 2025 | 6-K | Filing |
Mar 14, 2025 | S-8 POS | Filing |